Novartis: Over 40 research results of Aduitinib presented at the 31st Annual Meeting of the European Hematology Association.

Nuocheng Jianhua announced today that more than 40 research results of the company's independently developed novel BTK inhibitor, acalabrutinib, were presented at the 31st annual meeting of the European Hematology Association, demonstrating for the first time the effectiveness and safety of acalabrutinib in the treatment of previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma in Europe and America.